Despite inquiry, FDA AdCom backs BMS Abecma approval
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients.
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients.
The initiative will offer pharmaceutical companies new opportunities to execute innovations in clinical research.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech
Tierra raises $11.4 in Series A round for predictive AI protein maker
CTS Europe: The roadmap for generative AI in the pharma industry
Sonrai Analytics and Candel to advance cancer treatment using AI